This compound serves as a key intermediate in the synthesis of Bexarotene, a retinoid X receptor (RXR) agonist used in the treatment of cutaneous T-cell lymphoma. It is primarily employed in pharmaceutical research and development for creating bioactive compounds with potential therapeutic applications in oncology and dermatology. The unique tetralin-derived structure allows for modifications that enhance biological activity, stability, and selectivity in drug design. Additionally, it may be explored in the development of other retinoid analogs for anti-inflammatory, antioxidant, or chemopreventive purposes.